Milan, Italy

PierNicola Giraldi


Average Co-Inventor Count = 6.1

ph-index = 5

Forward Citations = 81(Granted Patents)


Company Filing History:


Years Active: 1977-1981

Loading Chart...
12 patents (USPTO):Explore Patents

Title: The Innovative Contributions of PierNicola Giraldi

Introduction

PierNicola Giraldi is a prominent inventor based in Milan, Italy. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds with anti-allergy properties. With a total of 12 patents to his name, Giraldi's work has the potential to impact the treatment of allergic conditions.

Latest Patents

Among his latest patents, Giraldi has developed 3,4-Dihydro-quinazoline derivatives. These compounds, such as 6-carboxy-2-(2'-ethoxy-phenyl)-3,4-dihydro-4-oxo-quinazoline, are disclosed for their anti-allergy properties. They can be utilized in the treatment of various allergic conditions. Additionally, he has patented substituted 2-vinyl-chromones, which feature an alkyl or alkenyl substituent at the 3-position and a styryl substituent at the 2-position. These compounds also exhibit anti-allergy activity and can be used to treat allergic conditions.

Career Highlights

Giraldi has worked with notable companies, including Carlo Erba S.p.a. and Carlo Erba, S. P. A. His experience in these organizations has contributed to his expertise in pharmaceutical innovations.

Collaborations

Throughout his career, Giraldi has collaborated with esteemed colleagues such as Gianfederico Doria and Francesco Lauria. These partnerships have likely enhanced his research and development efforts.

Conclusion

PierNicola Giraldi's innovative work in the field of anti-allergy compounds showcases his dedication to improving healthcare solutions. His contributions through patents and collaborations highlight his role as a significant inventor in the pharmaceutical industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…